The shortages have since been resolved, but patients are still clamoring for cheaper access and more insurance coverage, which is expected to continue to drive demand
Type 2 DM Pharmacotherapy Selection Update and Management Considerations for Older Adults: Key updates related to T2DM pharmacotherapy from the 2023 ADA guideline include the following: Further emphasis for selecting pharmacotherapy (first-line and add-on therapies) based upon patient specific factors, comorbidities, and treatment goals (e.g., cardiorenal risk reduction in high-risk patients, glycemic and weight management, access, etc.)
This is often easier when the primary goal is consistency
doi: 10.1007/s00216-006-0529-8 105 HuangYWangQGaoJLinZBauelosGSYuanLet al
This is common in women with PCOS or metabolic dysfunction
Millions of people take semaglutide for weight loss, but those with an underactive thyroid face unique considerations